Morning Overview on MSN
A cancer drug just became the first FDA-cleared treatment for a common breast-cancer subtype
Patients with the most common molecular subtype of advanced breast cancer now have a targeted drug approved specifically for ...
Research led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified immune ...
Key Points Interested in OnKure Therapeutics, Inc.? Here are five stocks we like better. OnKure Therapeutics is advancing two ...
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s ...
New Mexico Cancer Center will become the first healthcare provider in the state to offer estrogen receptor (ER)-targeted PET ...
After nearly a year of intense treatment for stage three breast cancer, longtime Hallmark actress and director Yan-Kay ...
Between August and December of 2024, I went from having a clear mammogram and a clean bill of health to being diagnosed with ...
I remember the day I first knew something was wrong, about a month after I turned 31. I’m a school nurse, so I have summers ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Datroway and Trodelvy are offering patients with advanced triple-negative breast cancer a more targeted alternative to chemotherapy, improving survival and slowing ...
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.
US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results